Featured Articles
Alkahest’s oral small molecule drug aims to report on a Phase IIa study for age-related macular degeneration
Alkahest Inc., a clinical stage biopharmaceutical company based in San Carlos, California, has announced that an experimental drug, AKST4290, in a Phase IIa study for AMD, showed that 83% of patients maintained or improved their visual acuity, and 21% of patients gained at least 15 letters in BCVA. The open-label Hungarian trial enrolled 29 patients […]
Read full storyClinical research for systematic reviews and meta-analysis focuses on cn-AMD, DMO, RVO-MO and m-CNV
A systematic review and meta-analysis, published by British Medical Journal Open (2019), has included 19 randomized controlled trials (RCTs) to evaluate the comparative effectiveness and safety of intravitreal bevacizumab (Avastin), ranibizumab (Lucentis) and aflibercept (Eylea) for patients with cn-AMD, DMO, RVO-MO and m-CNV. According to the study review, intravitreal bevacizumab was as effective as ranibizumab […]
Read full storyA drug delivery approach for a thermoresponsive polymer shows sustained anti-VEGF treatment for AMD
Researchers in an independent Australian federal research agency (CSIRO), Victoria, Australia, have demonstrated that a novel polymer synthesizing two anti-VEGF treatments (bevacizumab and aflibercept) may be used to extend drug delivery release profiles over a 183 day period. As anti-VEGF intravitreal injections generally require burdensome monthly treatments, the new reverse thermoresponsive polymer (RTP) may significantly […]
Read full story